Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: An update

Marta Del Campo, Brit Mollenhauer, Antonio Bertolotto, Sebastiaan Engelborghs, Harald Hampel, Anja Hviid Simonsen, Elisabeth Kapaki, Niels Kruse, Nathalie Le Bastard, Sylvain Lehmann, Jose L. Molinuevo, Lucilla Parnetti, Armand Perret-Liaudet, Javier Sáez-Valero, Esen Saka, Andrea Urbani, Eugeen Vanmechelen, Marcel Verbeek, Pieter Jelle Visser, Charlotte Teunissen

Research output: Contribution to journalArticlepeer-review

Abstract

Early diagnosis of neurodegenerative disorders such as Alzheimers (AD) or Parkinsons disease (PD) is needed to slow down or halt the disease at the earliest stage. Cerebrospinal fluid (CSF) biomarkers can be a good tool for early diagnosis. However, their use in clinical practice is challenging due to the high variability found between centers in the concentrations of both AD CSF biomarkers (A42, total tau and phosphorylated tau) and PD CSF biomarker (α-synuclein). Such a variability has been partially attributed to different preanalytical procedures between laboratories, thus highlighting the need to establish standardized operating procedures. Here, we merge two previous consensus guidelines for preanalytical confounding factors in order to achieve one exhaustive guideline updated with new evidence for A42, total tau and phosphorylated tau, and α-synuclein. The proposed standardized operating procedures are applicable not only to novel CSF biomarkers in AD and PD, but also to biomarkers for other neurodegenerative disorders.

Original languageEnglish
Pages (from-to)419-430
Number of pages12
JournalBiomarkers in Medicine
Volume6
Issue number4
DOIs
Publication statusPublished - Aug 2012

Keywords

  • Alzheimers disease
  • biomarkers
  • CSF
  • early diagnosis
  • guidelines
  • Parkinsons disease
  • preanalytical factors
  • recommendations
  • standard operating procedures

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Fingerprint Dive into the research topics of 'Recommendations to standardize preanalytical confounding factors in Alzheimers and Parkinsons disease cerebrospinal fluid biomarkers: An update'. Together they form a unique fingerprint.

Cite this